EcoDrugPlus

Polo Like Kinase 1

Ensembl ID : ENSFHEG00000004658
Gene Symbol: PLK1
4 Cross references
187 Possible Orthologues:

Polo Like Kinase 4

Ensembl ID : ENSFHEG00000009369
Gene Symbol: PLK4
3 Cross references
215 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSFHEG00000001117
Gene Symbol: PARP1
3 Cross references
209 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 2

Ensembl ID : ENSFHEG00000023027
Gene Symbol: PARP2
3 Cross references
186 Possible Orthologues:

Poly(Adp-Ribose) Polymerase Family Member 3

Ensembl ID : ENSFHEG00000006307
Gene Symbol: PARP3
3 Cross references
199 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSFHEG00000021792
Gene Symbol: PORCN
3 Cross references
195 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSFHEG00000011518
Gene Symbol: KCNMA1
3 Cross references
244 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSFHEG00000021161
Gene Symbol: KCNMA1
3 Cross references
227 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily N Member 4

Ensembl ID : ENSFHEG00000009864
Gene Symbol: KCNN4
3 Cross references
190 Possible Orthologues:

Potassium Channel Subfamily K Member 9-Like

Ensembl ID : ENSFHEG00000004141
Gene Symbol: LOC105924145
3 Cross references
219 Possible Orthologues:

Potassium Channel, Subfamily K, Member 2b

Ensembl ID : ENSFHEG00000001196
Gene Symbol: KCNK2B
2 Cross references
214 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 11

Ensembl ID : ENSFHEG00000011225
Gene Symbol: KCNJ11
1 Cross references
189 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).